Semaglutide 6mg
GLP-1 receptor agonist (31-amino acid lipidated peptide)
CAS: 910463-68-2
~14.9%
STEP-1 weight loss
Wilding NEJM 2021
~7 days
Half-life
Clinical PK
2017
FDA approval
Ozempic
Technical Data & References
Chemistry, identifiers, and primary literature for Semaglutide — available as lyophilized powder on Clav Tides.
- Short Sequence
- H-{Aib}-EGTFTSDVSSYLEGQAAKEFIAWLVRGRG-OH (Lys²⁶ side-chain modified)
- Full Sequence
- His-{Aib}-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH (Lys²⁶ side-chain: γGlu-C18 diacid via AEEA-AEEA linker)
- Salt Form
- Free acid
- # Amino Acids
- 31
- Purity
- ≥98%
- Molecular Formula
- C187H291N45O59
- Molecular Weight
- 4113.58 g/mol
- CAS Number
- 910463-68-2
- PubChem CID
- 56843331
- Source
- Synthetic
- Appearance
- Lyophilized powder
- Availability
- Lyophilized powder — Clav Tides
Primary Literature
- 1.
Lau J, Bloch P, Schäffer L, et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. J Med Chem. 2015 Sep 24;58(18):7370-80.
- 2.
Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021 Mar 18;384(11):989-1002.
- 3.
Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016 Nov 10;375(19):1834-1844.
Research use only. Data compiled from published literature and regulatory registries. Semaglutide 6mg is supplied for in-vitro laboratory research — not for human consumption, injection, or therapeutic use.
Reconstitution Protocol
BAC Water
1.5mL
Final Concentration
4 mg/mL
Per Dose
2.4 mg = 0.6 mL (60 IU) · 1.0 mg = 0.25 mL · 0.5 mg = 0.125 mL
Titrate from 0.25 mg over 16+ weeks to minimize GI adaptation period
Research Stacks
| Compound | Why Researchers Stack It |
|---|---|
| BPC-157 | Mitigates GLP-1-induced gastric/GI side effects during titration |
| Tirzepatide | Dual GIP/GLP-1 alternative with larger effect size |
| Cagrilintide | Amylin analog — researched as a weight-loss potentiator with Semaglutide |
Published References
- 1.Wilding JPH, Batterham RL, Calanna S, et al.. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine (2021) PMID: 33567185
- 2.Knudsen LB, Lau J. The Discovery and Development of Liraglutide and Semaglutide. Frontiers in Endocrinology (2019) PMID: 31031711
Research Use Only. This product is intended for in-vitro laboratory research only. Not for human consumption, injection, or therapeutic use. Not medical advice. Always consult applicable regulations in your jurisdiction.
Price Comparison
| Supplier | Purity | Price | Shipping |
|---|---|---|---|
| our verified supplier | >98% HPLC | $71.99 | Free over $200 |
| Generic Research Suppliers | Varies (often <95%) | Similar–Higher | Varies |
| Pharmaceutical (Rx only) | Pharmaceutical grade | Not available for research | Rx required |
Buy Peptides Compounds
Tirzepatide 60mg
Tirzepatide 15mg
Cagri-Reta 10mg
Cagri-Reta 5mg
Semaglutide 6mg
$71.99